Oliver C Cohen, Maximillian H Brodermann, Iona J Blakeney, Shameem Mahmood, Sajitha Sachchithanantham, Sriram Ravichandran, Steven Law, Helen J Lachmann, Carol J Whelan, Rakesh Popat, Neil Rabin, Kwee Yong, Charalampia Kyriakou, Raakhee Shah, Simon Cheesman, Sarah Worthington, Philip Hawkins, Julian D Gillmore, Ashutosh D Wechalekar
Background: Daratumumab is a monoclonal antibody, which targets CD38; an antigen expressed on malignant plasma cells in AL amyloidosis thus providing a rationale for its use. Method: Patients treated with daratumumab monotherapy (2016-2019) for relapsed/refractory systemic AL amyloidosis were identified from the database at the UK National Amyloidosis Centre. Results: Of 50 evaluable patients, haematological responses at 3 months were: CR - 19 (38%), VGPR - 14 (28%), PR - 9 (18%) and no response - 8 (16%)...
September 2020: Amyloid: the International Journal of Experimental and Clinical Investigation